← Back to Search

Beta-2 Agonist

Test 0.09 mg for Asthma

Phase 3
Waitlist Available
Research Sponsored by Aurobindo Pharma Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over a period of 4 weeks
Awards & highlights

Study Summary

Pharmacodynamic bioequivalence study of Albuterol Sulfate Inhalation Aerosol 0.09 mg

Eligible Conditions
  • Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over a period of 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and over a period of 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post-dose PD20

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Test 0.18 mgExperimental Treatment2 Interventions
Group II: Test 0.09 mgExperimental Treatment2 Interventions
Group III: Reference 0.09 mgActive Control2 Interventions
Group IV: Reference 0.18 mgActive Control2 Interventions
Group V: Zero dose:Placebo Group2 Interventions

Find a Location

Who is running the clinical trial?

Aurobindo Pharma LtdLead Sponsor
7 Previous Clinical Trials
26,457 Total Patients Enrolled
1 Trials studying Asthma
1,550 Patients Enrolled for Asthma
Joseph Marialouis, MDStudy DirectorAurobindo Pharma Ltd

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025